Primary adenoid cystic carcinoma (PACC) of the skin is a rare tumor with fewer than 70 cases studied in detail in the English literature. This type of tumor shows a prolonged course and a growth pattern usually manifested by multiple local recurrences and has a low potential for distant metastases. The most important modality for primary treatment is surgical resection followed by radiotherapy. We report a woman aged 43 years at the time of diagnosis, who presented with a slow-growing nodule in the right axilla without lymph node enlargement. A wide local excision was performed, and the histology revealed an adenoid cystic carcinoma. During the next 24 years, another four local recurrences were excised (the last one in 2015) and confirmed histologically to be adenoid cystic carcinoma. The patient was given 44 Gy of radiotherapy after the second surgery in 1996. PACC of the skin is a rare tumor with insufficient data concerning the efficacy of the surgical technique and chemotherapy and radiotherapy treatment, even more so in the case of multiple recurrences. After the last recurrence, the patient was offered an active follow-up based on the long tumor-free intervals in the past and because the site of the primary tumor allowed further surgical excisions in future recurrences.

Adenoid cystic carcinoma (ACC) is a malignant tumor which develops in areas with secretory glands, most commonly in the head and neck region [1]. Rarely, ACC arises in the airways, breast, vulva, and skin. It was first described by Theodor Billroth as ‘cylindroma' in 1859 [2]. The name cylindroma originated from the specific appearance of the tumor cells with cylindrical pseudolumina or pseudospaces. Primary ACC (PACC) of the skin is a rare tumor first described by Boggio [3] in 1975, of which fewer than 70 cases have so far been studied in detail and reported in the English literature [4]. PACC has a low potential for distant metastases but has a very aggressive infiltrative growth pattern, frequent perineural invasion, and a high risk of local recurrence after excision [5]. The treatment depends on its size and location. Surgical techniques are reported as first-choice therapy for lesion excision. The high risk of local recurrence after surgery suggests that postoperative radiotherapy should be administered [6].

In 1991, a 43-year-old woman presented to the dermatologist with a 10-year history of an enlarging nodule in the right axilla. In the previous couple of years, there were several episodes of inflammation. Clinical exam showed a 2-cm nodule on the midaxillary line. The nodule was flesh-colored and mildly painful. There were no palpable lymph nodes in the axillary area. The patient had no significant medical history to report. A wide excision was performed, and the histological result showed ACC of the skin. Perineural invasion was not described. Macroscopically, the tumor nodule was solid and covered with connective tissue. In 1996, a similar nodule occurred on the postoperative cicatrix, and another excision was made. The histology result showed ACC - a local recurrence. Radiotherapy was offered and performed with 44 Gy administered.

In 2000, a local recurrence was suspected in the area of the previous surgical treatments, but postexcision histology showed connective tissue only. In 2006 and 2010, excisions were made after local recurrences of tumor formation in the operative cicatrix, which were diagnosed as ACC. All of the laboratory and imaging tests during the 24-year history of the disease were within normal ranges, and no metastatic disease was diagnosed. In March 2015, once again, growth in the postoperative cicatrix in the right axilla appeared. The entire postoperative cicatrix was excised, and a 1.5/1.5-cm nodule was found. Histology revealed an ACC (fig. 1), with the tumor cells arranged in multiple variously sized lobules. They showed an overall cribriform appearance of the tumor (fig. 2). The chest CT scan showed no pulmonary metastases, and the patient was offered an active follow-up.

Fig. 1

Low-powered view of a hematoxylin-eosin stained tumor specimen. The tumor reaches deep into the dermis, without any connection to the epidermis. It infiltrates the subcutaneous fat and is composed of solid alveolar structures consisting of uniform cells scattered around mucinous secretion, forming cribriform structures.

Fig. 1

Low-powered view of a hematoxylin-eosin stained tumor specimen. The tumor reaches deep into the dermis, without any connection to the epidermis. It infiltrates the subcutaneous fat and is composed of solid alveolar structures consisting of uniform cells scattered around mucinous secretion, forming cribriform structures.

Close modal
Fig. 2

Low-powered view of a hematoxylin-eosin stained tumor specimen. Small, uniform cells prevail, with rounded and oval nuclei and scarce cytoplasm. The lobules are surrounded by a thick hyaline membrane. The mitotic activity is low with a mitotic index of 2, 3 (×10). There is no perineural invasion.

Fig. 2

Low-powered view of a hematoxylin-eosin stained tumor specimen. Small, uniform cells prevail, with rounded and oval nuclei and scarce cytoplasm. The lobules are surrounded by a thick hyaline membrane. The mitotic activity is low with a mitotic index of 2, 3 (×10). There is no perineural invasion.

Close modal

PACC of the skin is a rare tumor with fewer than 70 cases reported in the English literature [4]. This type of carcinoma is commonly diagnosed in elderly and middle-aged patients. The average age at diagnosis is 59 years. It equally affects males and females, with a slight prevalence in females (54%) [7,8,9]. In 44% of the cases, there was a documented local recurrence with a follow-up period of 58 months. Metastases in other organs are rare and, in the event that they occur, the lung and lymph nodes are commonly affected sites [5]. The reported patient presented with PACC of the skin, first diagnosed in 1991, with four histologically confirmed local recurrences. There were no detailed case reports in the accessible literature on such series of local recurrences, only reports on a high risk of such recurrences. All four recurrences were surgically treated; after the second one, a decision for radiotherapy was made, and the latter was administered at a dose of 44 Gy. The last local recurrence we described was diagnosed in March 2015 and was treated only surgically. ACC of the skin most often presents a treatment challenge due to the rarity of the lesion [10]. Surgical resection is a primary treatment, usually followed by radiotherapy; chemotherapy is used in select cases. Wide excision is the most common surgical technique, which was performed in the reported patient as well. The recurrence rate after traditional wide excision is about 44%. There are reports of several cases managed with Mohs micrographic surgery. Xu et al. [5] reported 7 cases treated with Mohs micrographic surgery without local recurrences during the follow-up period. Nevertheless, the authors admit that the limited number of cases and the insufficient follow-up period do not allow drawing a definitive conclusion on the superiority of Mohs micrographic surgery over wide local excision. There are no studies in the literature indicating the best surgical approach, and there are no sufficient follow-up data in cases with multiple local recurrences either. Again, because of the rarity of PACC of the skin, there are no studies in the literature about the efficacy of radiotherapy and chemotherapy. Nevertheless, there are a few reports debating that radiotherapy in PACC of the skin can help in achieving locoregional control when given postoperatively [11]. Chemotherapy is usually reported in PACC of the skin in cases with advanced disease. Cisplatin-containing regimens (cisplatin and 5-fluorouracil, cisplatin and anthracyclines, cisplatin and vinorelbine) showed some response in isolated cases [12,13,14].

The reported patient presented with PACC of the skin, with multiple local recurrences treated with wide local excisions and radiotherapy, and without imaging evidence of metastatic disease. After the last local recurrence, the patient was offered an active follow-up, the decision being based on the long disease-free intervals between the local recurrences. Surgery remains a possible future option for treatment, as the localization of the tumor allows further excision in case of recurrences. Chemotherapy is not curative and could be reserved for metastatic disease, whereas radiotherapy could be used for future local control.

The corresponding author acknowledges that he is responsible for complying with ethical requirements and declares that the patient was correctly informed and written informed consent was obtained; the confidentiality of the patient was strictly preserved; the patient was informed about the submission of the manuscript and will be acquainted when the article is published, and the Principal of the Complex Cancer Center, Plovdiv, was informed and the manuscript was written according to the Ethical Codex of the institution.

There is no conflict of interest regarding the publication of this paper.

1.
Khan AJ, DiGiovanna MP, Ross DA, Sasaki CT, Carter D, Son YH, Haffty BG: Adenoid cystic carcinoma: a retrospective clinical review. Int J Cancer 2001;96:149-158.
2.
Alleyne CH, Bakay RA, Costigan D, Thomas B, Joseph GJ: Intracranial adenoid cystic carcinoma: case report and review of the literature. Surg Neurol 1996;45:265-271.
3.
Boggio R: Letter: adenoid cystic carcinoma of scalp. Arch Dermatol 1975;111:793-794.
4.
Rocas D, Asvesti C, Tsega A, Katafygiotis P, Kanitakis J: Primary adenoid cystic carcinoma of the skin metastatic to the lymph nodes: immunohistochemical study of a new case and literature review. Am J Dermatopathol 2014;36:223-228.
5.
Xu YG, Hinshaw M, Longley BJ, Ilyas H, Snow SN: Cutaneous adenoid cystic carcinoma with perineural invasion treated by Mohs micrographic surgery - a case report with literature review. J Oncol 2010;2010:469049.
6.
Maciejewski A, Szymczyk C, Wierzgon J: Outcome of surgery for adenoid cystic carcinoma of head and neck region. J Craniomaxillofac Surg 2002;30:59-61.
7.
Doganay L, Bilgi S, Aygit C, Altaner S: Primary cutaneous adenoid cystic carcinoma with lung and lymph node metastases. J Eur Acad Dermatol Venereol 2004;18:383-385.
8.
Boggio RR: Primary adenoid cystic carcinoma of the skin. Arch Pathol Lab Med 1985;109:707.
9.
Dores GM, Huycke MM, Devesa SS, Garcia CA: Primary cutaneous adenoid cystic carcinoma in the United States: incidence, survival, and associated cancers, 1976 to 2005. J Am Acad Dermatol 2010;63:71-78.
10.
Grahne B, Lauren C, Holsti LR: Clinical and histological malignancy of adenoid cystic carcinoma. J Laryngol Otol 1977;91:743-749.
11.
Kato N, Yasukawa K, Onozuka T: Primary cutaneous adenoid cystic carcinoma with lymph node metastasis. Am J Dermatopathol 1998;20:571-577.
12.
Ikegawa S, Saida T, Obayashi H, Sasaki A, Esumi H, Ikeda S, Kiyohara Y, Hayasaka K, Ishihara K: Cisplatin combination chemotherapy in squamous cell carcinoma and adenoid cystic carcinoma of the skin. J Dermatol 1989;16:227-230.
13.
Singh A, Ramesh V: Primary cutaneous adenoid cystic carcinoma with distant metastasis: a case report and brief literature review. Indian J Dermatol Venereol Leprol 2010;76:176-179.
14.
Yamada T, Mouri H, Izumi K, Takeuchi S, Ohtsubo K, Yamashita K, Yasumoto K, Kitamura S, Yano S: Combined chemotherapy with cisplatin plus vinorelbine showed efficacy in a case of metastatic primary cutaneous adenoid cystic carcinoma. Gan To Kagaku Ryoho 2010;37:1545-1548.
Open Access License / Drug Dosage / Disclaimer
Open Access License: This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial 3.0 Unported license (CC BY-NC) (www.karger.com/OA-license), applicable to the online version of the article only. Distribution permitted for non-commercial purposes only.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.